MX2010004529A - Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado. - Google Patents

Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.

Info

Publication number
MX2010004529A
MX2010004529A MX2010004529A MX2010004529A MX2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A
Authority
MX
Mexico
Prior art keywords
combination therapy
compositions
asthma
treatment
active agent
Prior art date
Application number
MX2010004529A
Other languages
English (en)
Spanish (es)
Inventor
Roch Thibert
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MX2010004529A publication Critical patent/MX2010004529A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010004529A 2007-10-25 2008-10-23 Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado. MX2010004529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25
PCT/CA2008/001874 WO2009052624A1 (en) 2007-10-25 2008-10-23 Combination therapy

Publications (1)

Publication Number Publication Date
MX2010004529A true MX2010004529A (es) 2010-05-10

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004529A MX2010004529A (es) 2007-10-25 2008-10-23 Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.

Country Status (19)

Country Link
US (1) US20100210611A1 (OSRAM)
EP (1) EP2211863A4 (OSRAM)
JP (1) JP2011500731A (OSRAM)
KR (1) KR20100072295A (OSRAM)
CN (1) CN101909626A (OSRAM)
AU (1) AU2008316283A1 (OSRAM)
CA (1) CA2701956A1 (OSRAM)
CO (1) CO6270213A2 (OSRAM)
CR (1) CR11439A (OSRAM)
DO (1) DOP2010000122A (OSRAM)
GT (1) GT201000107A (OSRAM)
IL (1) IL205182A0 (OSRAM)
MA (1) MA33705B1 (OSRAM)
MX (1) MX2010004529A (OSRAM)
NI (1) NI201000069A (OSRAM)
NZ (1) NZ584876A (OSRAM)
RU (1) RU2470639C2 (OSRAM)
WO (1) WO2009052624A1 (OSRAM)
ZA (1) ZA201002562B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20160339010A1 (en) 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
CN100346831C (zh) * 2001-09-19 2007-11-07 奥坦纳医药公司 Pde抑制剂与白三烯受体拮抗剂的并用药物
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
WO2005040123A1 (en) * 2003-10-10 2005-05-06 Synhton B. V. Solid-state montelukast
CN100512813C (zh) * 2004-02-06 2009-07-15 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
JP2008533174A (ja) * 2005-03-16 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤
HRP20160373T1 (hr) * 2005-03-16 2016-05-06 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava
JP2009509980A (ja) * 2005-09-28 2009-03-12 メルク フロスト カナダ リミテツド 篩分けされたラクトースを含むエアゾール粉末製剤

Also Published As

Publication number Publication date
EP2211863A1 (en) 2010-08-04
EP2211863A4 (en) 2012-07-25
RU2010120806A (ru) 2011-11-27
MA33705B1 (fr) 2012-11-01
GT201000107A (es) 2012-03-13
RU2470639C2 (ru) 2012-12-27
CA2701956A1 (en) 2009-04-30
WO2009052624A1 (en) 2009-04-30
CN101909626A (zh) 2010-12-08
CO6270213A2 (es) 2011-04-20
CR11439A (es) 2010-06-21
KR20100072295A (ko) 2010-06-30
IL205182A0 (en) 2010-11-30
ZA201002562B (en) 2011-06-29
NI201000069A (es) 2010-08-23
JP2011500731A (ja) 2011-01-06
WO2009052624A9 (en) 2010-11-25
AU2008316283A1 (en) 2009-04-30
NZ584876A (en) 2012-06-29
US20100210611A1 (en) 2010-08-19
DOP2010000122A (es) 2010-07-15

Similar Documents

Publication Publication Date Title
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
MX361886B (es) Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
NZ594210A (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
MX2008010172A (es) Suministro pulmonar de inhibidor de proteinasa alafa-i.
WO2005102431A3 (en) Aerosol delivery apparatus for pressure assisted breathing
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
MX2010004529A (es) Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
WO2007099329A3 (en) Nebulizer formulation
MX2014002465A (es) Composiciones acuosas que comprenden arbekacina.
MY179794A (en) Compound composition for inhalation used for treating asthma
WO2010048384A3 (en) Arformoterol and tiotropium compositions and methods for use
UA83018C2 (uk) Комбінація рофлуміласту і формотеролу для лікування захворювань дихальних шляхів
MX2010002633A (es) Composiciones para inahalacion de dheas.
HK1212902A1 (zh) 诸如nps89636的钙/阳离子感应受体(casr)拮抗剂在治疗炎性肺病(哮喘或copd)中的应用
GB0402679D0 (en) Organic compounds
WO2003094968A3 (en) Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
MX2013004575A (es) Disacaridos hipersulfatados para tratar trastornos relacionados con la elastasa.
HK40086548A (en) Use of agents for treatment of respiratory conditions
MX2008010757A (es) Combinaciones de esteroides y compuestos de metil-xantina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal